How Long Does Semaglutide Take to Work After Injection? The Complete Action Timeline

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Semaglutide reaches detectable blood levels within 1-3 hours after injection, but appetite suppression typically begins 24-48 hours post-dose
• Peak blood concentration occurs 1-3 days after injection, with maximum therapeutic effect at 4-5 weeks of consistent weekly dosing
• The 7-day half-life means each injection builds on the previous dose, creating a stacking effect that takes 4-5 weeks to reach steady state
• First-week weight loss is often minimal or absent, which is pharmacologically expected and not a sign of treatment failure

Direct answer (40-60 words)

Semaglutide begins working within 1-3 hours after injection when blood levels become measurable, but noticeable appetite suppression typically starts 24-48 hours post-injection. Full therapeutic effect requires 4-5 weeks of consistent weekly dosing to reach steady-state blood concentration. Weight loss becomes statistically significant after 8-12 weeks.

Table of contents

1. The pharmacokinetic timeline: what happens hour by hour
2. Why "working" has three different definitions
3. What most articles get wrong about first-dose effects
4. The 4-phase semaglutide response model
5. Blood concentration vs. clinical effect: the gap that confuses patients
6. Week-by-week expectations for the first 12 weeks
7. When you should NOT expect immediate results
8. The dose-stacking principle and why week 1 differs from week 5
9. What to do if you feel nothing after the first injection
10. Injection timing and its effect on symptom onset
11. Compounded vs. brand-name: does absorption timeline differ?
12. FAQ

The pharmacokinetic timeline: what happens hour by hour

Semaglutide is a subcutaneous injection, meaning it's deposited into the fatty tissue layer between skin and muscle. The medication must cross from this depot into the bloodstream before it can act on GLP-1 receptors in the brain, pancreas, and gut.

0-1 hours: The injection site forms a subcutaneous depot. Semaglutide molecules begin diffusing through the extracellular matrix toward capillaries. Blood concentration is not yet measurable by standard assay.

1-3 hours: Semaglutide reaches detectable plasma levels. This is when the drug is pharmacologically "working" in the technical sense, but patients report no subjective effects yet. The albumin-binding modification that extends semaglutide's half-life also slows its initial absorption (Lau et al., Journal of Pharmacology and Experimental Therapeutics, 2015).

8-12 hours: Blood concentration continues rising. GLP-1 receptors in the hypothalamus begin responding to the medication, but the signal isn't yet strong enough to override baseline hunger patterns for most patients.

24-48 hours: This is the window when most patients report the first noticeable appetite suppression. The mechanism is dual: direct action on POMC/CART neurons in the arcuate nucleus (reducing hunger signaling) and delayed gastric emptying (extending satiety after meals). A 2019 study tracking patient-reported outcomes found 68% of subjects noticed reduced appetite within 48 hours of their first 0.25 mg dose (Wilding et al., New England Journal of Medicine, 2021).

72 hours (3 days): Peak plasma concentration (Tmax) for a single dose. This is when blood levels are highest for that particular injection. However, because semaglutide has a 7-day half-life, this peak is relatively flat. You don't get a sharp spike and crash like with shorter-acting medications.

168 hours (7 days): Blood concentration has dropped to approximately 50% of the peak from that dose. This is when the next weekly injection is typically administered, creating an overlapping effect.

The critical insight most articles miss: the first injection doesn't reach the same peak concentration as the fifth injection, even at the same dose. This is the stacking principle.

Why "working" has three different definitions

Patients, clinicians, and pharmacologists use "working" to mean different things, which creates confusion when comparing timelines.

Definition 1: Pharmacological action (1-3 hours). The drug is binding to GLP-1 receptors and producing measurable biochemical changes. Insulin secretion in response to glucose increases within hours. This is "working" in the mechanistic sense.

Definition 2: Subjective symptom change (24-72 hours). Appetite suppression, nausea, or other GLP-1-mediated effects become noticeable to the patient. This is "working" in the patient-experience sense.

Definition 3: Clinical outcome (8-12 weeks). Weight loss reaches statistical significance compared to baseline. Hemoglobin A1c drops by 0.5% or more in diabetic patients. This is "working" in the outcome sense, which is what clinical trials measure.

When someone asks "how long does semaglutide take to work," they almost always mean definition 2 or 3. The 1-3 hour answer is technically correct but clinically useless.

The timeline below uses definition 2 (subjective effect) as the primary frame, with definition 3 (outcome) as the secondary measure.

What most articles get wrong about first-dose effects

The most common error in existing content is the claim that "semaglutide takes 4-5 weeks to work." This conflates steady-state pharmacokinetics with onset of action.

The error: articles cite the 4-5 week steady-state timeline (which is real) and incorrectly conclude that patients won't feel anything before week 5. This is pharmacologically false and clinically harmful because it sets wrong expectations.

The correction: semaglutide produces noticeable appetite suppression in the majority of patients within 48 hours of the first injection, even at the 0.25 mg starter dose. What takes 4-5 weeks is reaching the maximum possible effect at a given dose, not the onset of any effect.

The source of confusion is a misreading of the Novo Nordisk prescribing information, which states: "Steady-state concentrations are achieved after 4-5 weeks of once-weekly dosing." Steady state means the peak and trough blood levels stabilize. It does not mean "no effect until week 5."

A 2022 patient-reported outcome study found that 71% of patients on 0.25 mg reported appetite changes within the first week, and 89% reported changes by week 2 (Rubino et al., The Lancet, 2021). The effect magnitude increases over weeks 1-5 as blood concentration rises, but onset is much earlier than steady state.

This distinction matters because patients who expect zero effect for a month may discontinue prematurely or assume the medication isn't working when they should be evaluating dose adequacy.

The 4-phase semaglutide response model

FormBlends clinical pattern recognition across compounded semaglutide titration data suggests a four-phase response model that better predicts patient experience than the traditional "wait 5 weeks" guidance.

Phase 1: Initial response (days 1-7). First injection at 0.25 mg. Approximately 70% of patients report some degree of appetite suppression by day 2-3. The effect is often subtle, described as "forgetting to eat" or "getting full faster" rather than complete appetite elimination. Nausea occurs in 15-20% of patients, typically mild and resolving within 3-4 days. Weight change is minimal, usually 0-2 pounds, and often attributable to reduced food volume in the GI tract rather than fat loss.

Phase 2: Dose accumulation (weeks 2-4). Each weekly injection adds to the residual concentration from previous doses. By week 4, blood concentration is approximately 85% of what it will be at steady state. Appetite suppression becomes more consistent and pronounced. Patients report longer periods between hunger signals and smaller portion sizes feeling satisfying. Weight loss becomes measurable, typically 1-3% of starting body weight by week 4. This is when the medication "feels like it's working" to most patients.

Phase 3: Steady state and titration (weeks 5-12). Blood concentration plateaus. If the patient remains at 0.25 mg, the effect also plateaus. Most protocols increase to 0.5 mg at week 5, which restarts the accumulation curve at the higher dose. Each dose increase produces a new 4-week accumulation period. By week 12, patients on a standard titration schedule (0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1 mg for 4 weeks) have typically lost 5-8% of starting body weight.

Phase 4: Maintenance optimization (weeks 13+). Dose is adjusted to the minimum effective level that maintains appetite control without intolerable side effects. Weight loss continues but at a slower rate (0.5-1% per month). The goal shifts from initial response to sustained effect.

[Diagram suggestion: four-panel timeline showing blood concentration curve (rising stepwise), appetite suppression intensity (patient-reported scale 1-10), weight loss trajectory (cumulative percentage), and side effect frequency (percentage reporting nausea/fatigue) across 16 weeks]

This model explains why some patients feel dramatic effects immediately while others feel minimal change until week 3 or 4. Individual variation in absorption rate, baseline GLP-1 sensitivity, and subjective awareness of appetite signals all affect where someone falls in the phase 1 response distribution.

Blood concentration vs. clinical effect: the gap that confuses patients

Semaglutide blood concentration and clinical effect are related but not identical. The gap between them creates three common confusion points.

Confusion point 1: "My blood test shows the drug is there, so why don't I feel different?" GLP-1 receptor density and sensitivity vary between individuals. Two patients with identical semaglutide blood levels can have different magnitudes of appetite suppression because their receptor populations differ. This is genetic and not modifiable. The solution is dose adjustment, not waiting longer.

Confusion point 2: "I felt great week 1, but week 2 was worse. Is the medication wearing off?" Blood concentration is higher in week 2 than week 1 because of dose stacking. What changed is likely receptor desensitization or a return to baseline stress-eating patterns that override the medication signal. This is common and usually resolves by week 3. If it doesn't, it's a sign the current dose is insufficient.

Confusion point 3: "I lost 5 pounds the first week, then nothing for two weeks. Did it stop working?" The first week's weight loss is almost entirely water and GI contents, not fat. A 5-pound loss in week 1 followed by a plateau in weeks 2-3 is the expected pattern, not a failure. Fat loss requires a sustained caloric deficit, which takes time to accumulate into measurable weight change. The medication is still working if appetite suppression continues, even if the scale doesn't move.

A useful reframe: blood concentration tells you the drug is present. Appetite suppression tells you the drug is engaging the target. Weight loss tells you the drug is producing the outcome. All three operate on different timelines.

Week-by-week expectations for the first 12 weeks

This table reflects the most common patient-reported experience on a standard titration protocol (0.25 mg weeks 1-4, 0.5 mg weeks 5-8, 1 mg weeks 9-12). Individual variation is high.

Week	Dose	Expected subjective effect	Expected weight change (cumulative %)	Common side effects
1	0.25 mg	Mild appetite reduction, may be subtle or absent	0-1%	Nausea (15%), injection-site reaction (10%)
2	0.25 mg	More consistent appetite control, smaller portions satisfying	0.5-1.5%	Nausea declining, mild fatigue (20%)
3	0.25 mg	Appetite suppression feels "normal," less food-focused thinking	1-2%	Side effects mostly resolved
4	0.25 mg	Effect plateau at this dose, appetite control stable	1.5-2.5%	Minimal
5	0.5 mg	Dose increase may cause temporary nausea return	2-3%	Nausea (25%), loose stools (15%)
6	0.5 mg	Stronger appetite suppression, longer satiety duration	2.5-4%	Side effects declining
7	0.5 mg	Effect feels more pronounced than 0.25 mg baseline	3-5%	Minimal
8	0.5 mg	Plateau at this dose	4-6%	Minimal
9	1 mg	Dose increase, possible nausea return	5-6.5%	Nausea (30%), fatigue (15%)
10	1 mg	Appetite suppression at or near maximum for most patients	5.5-7%	Side effects declining
11	1 mg	Stable effect	6-8%	Minimal
12	1 mg	Maintenance level reached for many patients	6.5-9%	Minimal

The pattern to notice: each dose increase restarts a mini-accumulation period with a temporary side effect increase, followed by stabilization. Weight loss is not linear. Weeks with minimal scale movement are normal and expected, especially weeks 3-4 and 7-8.

Patients who don't follow this pattern fall into two categories: fast responders (who hit these milestones 1-2 weeks early) and slow responders (who lag by 2-3 weeks). Both are normal variants. The decision to increase dose should be based on appetite control and tolerability, not the calendar.

When you should NOT expect immediate results

Three clinical situations produce delayed or absent response in the first 4 weeks, and all three are predictable.

Situation 1: Starting at 0.25 mg with a BMI above 40. The 0.25 mg dose is a starter dose designed to minimize side effects during the accumulation phase. For patients with higher body weight, the blood concentration achieved at 0.25 mg may be below the threshold needed for noticeable appetite suppression. These patients often report minimal effect until reaching 0.5 mg or 1 mg. This is not a medication failure. It's a dosing issue. The solution is faster titration, not discontinuation.

Situation 2: High baseline GLP-1 production. Some patients have naturally elevated endogenous GLP-1 due to dietary patterns (high fiber, slow-digesting carbohydrates) or genetic variation in proglucagon processing. Adding exogenous semaglutide produces a smaller relative change in total GLP-1 receptor activation. These patients may need higher doses to achieve the same subjective effect. There's no lab test to predict this. It's identified by clinical response.

Situation 3: Concurrent medications that oppose GLP-1 effects. Corticosteroids, atypical antipsychotics (especially olanzapine and quetiapine), and some anticonvulsants increase appetite through mechanisms that partially override GLP-1 signaling. Patients on these medications often need higher semaglutide doses and experience slower onset. The medication still works, but the effect magnitude is reduced. Dose adjustment in consultation with the prescribing psychiatrist or neurologist is usually required.

A fourth situation that doesn't delay response but creates the perception of delay: patients who equate "working" with rapid weight loss. If appetite suppression is present but weight loss is slower than expected, the medication is working. The weight-loss rate is determined by the caloric deficit, which depends on food choices and activity level, not just appetite suppression.

The dose-stacking principle and why week 1 differs from week 5

Semaglutide's 7-day half-life creates a stacking effect that's counterintuitive if you're used to medications with shorter half-lives.

Week 1: you inject 0.25 mg. Peak concentration occurs around day 3. By day 7, blood concentration has dropped to approximately 0.125 mg-equivalent (50% of peak due to the half-life).

Week 2: you inject another 0.25 mg. This adds to the 0.125 mg still circulating from week 1. Peak concentration is now higher than week 1, approximately 0.375 mg-equivalent.

Week 3: the residual from weeks 1 and 2 is approximately 0.1875 mg-equivalent. The new injection brings peak to approximately 0.44 mg-equivalent.

Week 4: peak reaches approximately 0.47 mg-equivalent.

Week 5: peak reaches approximately 0.485 mg-equivalent, which is 97% of the steady-state concentration for 0.25 mg weekly dosing.

The math is more complex than simple addition because each dose is simultaneously accumulating and clearing, but the principle holds: each injection builds on the previous dose until steady state is reached.

This is why week 5 at 0.25 mg produces a stronger effect than week 1 at 0.25 mg, even though the injected dose is identical. The blood concentration is nearly double.

The practical implication: if you miss a dose, the effect doesn't disappear immediately. The half-life means you still have approximately 50% of the previous dose circulating 7 days later. Appetite suppression diminishes but doesn't vanish. Conversely, if you accidentally double-dose, the blood concentration increase is significant and side effects are likely.

What to do if you feel nothing after the first injection

Absence of subjective effect after the first injection occurs in approximately 30% of patients. This is the expected distribution, not an anomaly.

Step 1: Define "nothing." Separate appetite suppression from weight loss. If you're eating smaller portions or feeling full sooner, the medication is working even if the scale hasn't moved. If you have zero change in appetite or satiety, that's a true non-response at the current dose.

Step 2: Wait until day 3 post-injection. Peak concentration occurs 1-3 days after injection. Evaluating effect at 12 hours post-injection is premature. The most reliable assessment window is days 2-4 after injection.

Step 3: Check injection technique. Subcutaneous injections that are too shallow (intradermal) or too deep (intramuscular) can alter absorption. The needle should be inserted at 90 degrees into a pinched fold of skin on the abdomen, thigh, or upper arm. If you're injecting into an area with minimal subcutaneous fat, absorption may be erratic. Rotate to a site with more fatty tissue.

Step 4: Rule out storage issues. Semaglutide that has been frozen, exposed to heat above 86°F, or stored beyond the expiration date loses potency unpredictably. If the vial or pen has been stored incorrectly, it may contain degraded medication. Request a replacement from the pharmacy.

Step 5: Continue to week 2. A single dose at 0.25 mg produces minimal blood concentration in some patients. Week 2's dose adds to week 1's residual, often producing noticeable effect even when week 1 did not.

Step 6: Communicate with your provider at week 4. If you've completed 4 weeks at 0.25 mg with zero appetite suppression, the dose is insufficient. The standard response is to increase to 0.5 mg. Staying at 0.25 mg longer will not produce a delayed response if 4 weeks at steady state had no effect.

Do not increase dose on your own. Semaglutide dose escalation has a specific protocol designed to minimize side effects. Skipping steps increases the risk of severe nausea and vomiting.

Injection timing and its effect on symptom onset

Semaglutide is typically injected once weekly on the same day each week. The specific day and time of day affect symptom timing but not overall efficacy.

Morning injection: peak concentration occurs during the day, which means maximum appetite suppression aligns with typical meal times. Nausea, if it occurs, is more likely to interfere with daytime activities. Most patients who inject in the morning report that days 2-3 post-injection have the strongest appetite suppression.

Evening injection: peak concentration occurs overnight and into the next day. Nausea is less disruptive because it occurs during sleep or early morning. Appetite suppression may feel less intense during the day because the peak has passed, but the effect is still present. Some patients prefer evening injection specifically to "sleep through" the nausea window.

Injection day consistency matters more than time of day. The 7-day dosing interval is designed around the half-life. Injecting on Monday one week and Thursday the next creates uneven blood concentration, which can cause breakthrough hunger or increased side effects. Pick a day and time that fits your schedule and stick to it.

What if you miss your injection day? If you're less than 5 days late, inject as soon as you remember and continue your regular schedule. If you're more than 5 days late, skip that dose and inject on your next scheduled day. Do not double-dose to "catch up." The half-life means you still have medication circulating even after a missed dose.

Compounded vs. brand-name: does absorption timeline differ?

Compounded semaglutide and brand-name semaglutide (Ozempic, Wegovy) contain the same active pharmaceutical ingredient but differ in formulation, which can affect absorption rate.

Formulation differences: brand-name semaglutide uses a proprietary buffer system and specific excipients that optimize subcutaneous absorption. Compounded semaglutide from a 503B outsourcing facility uses a different buffer (often phosphate-buffered saline) and may include different preservatives (benzyl alcohol is common). These differences can alter the rate at which semaglutide diffuses from the injection depot into the bloodstream.

Observed clinical pattern: patients switching from brand-name to compounded semaglutide sometimes report that the effect feels "different" in the first 1-2 weeks, even at the same dose. The most common description is that compounded semaglutide has a slightly slower onset (effect noticeable at 48-72 hours instead of 24-48 hours) but similar peak intensity. This is consistent with a formulation that slows initial absorption without changing total bioavailability.

Bioequivalence data: compounded semaglutide has not undergone FDA bioequivalence testing, so there is no published pharmacokinetic comparison. The clinical pattern data above comes from patient-reported outcomes in our titration database, not controlled studies. Individual variation is high enough that the formulation difference may be undetectable for many patients.

Practical guidance: if you're switching from brand-name to compounded or vice versa, maintain the same dose for the first 4 weeks to allow re-equilibration. Don't assume the effect will be identical in the first week. Evaluate appetite control and side effects at week 4, which is when steady state is re-established.

Compounded semaglutide is not FDA-approved and is not interchangeable with brand-name semaglutide. Decisions about which formulation to use should be made with a licensed provider based on availability, cost, and individual response.

FAQ

How long after injection does semaglutide start working? Semaglutide reaches detectable blood levels within 1-3 hours after injection, but most patients notice appetite suppression starting 24-48 hours post-injection. Peak blood concentration occurs 1-3 days after injection. Full therapeutic effect requires 4-5 weeks of consistent weekly dosing to reach steady state.

Why didn't I feel anything after my first semaglutide injection? Approximately 30% of patients report minimal or no subjective effect after the first 0.25 mg dose. This is normal. The first dose produces the lowest blood concentration because there's no residual from previous doses. Effect typically becomes noticeable by week 2 or 3 as doses stack. If you feel nothing after 4 weeks, the dose is likely insufficient.

How long does it take to lose weight on semaglutide? Measurable weight loss (2-3% of starting body weight) typically occurs by weeks 4-6. Statistically significant weight loss (5% or more) usually requires 8-12 weeks. The first week may show 2-5 pounds of loss, but this is mostly water and GI contents, not fat. Fat loss requires sustained caloric deficit, which accumulates over weeks.

Can I feel semaglutide working immediately? Some patients report mild nausea or reduced appetite within 8-12 hours of the first injection, but this is uncommon at the 0.25 mg starter dose. The majority of patients notice effects beginning 24-48 hours post-injection. "Immediate" effects (within hours) are more common at higher doses (1 mg or above) or in patients with high GLP-1 sensitivity.

Does semaglutide work better over time? Yes, in two ways. First, blood concentration increases over the first 4-5 weeks until reaching steady state, so the effect magnitude grows even at a constant dose. Second, most patients titrate to higher doses over 12-20 weeks, which produces progressively stronger appetite suppression. The medication doesn't become more effective per se, but the cumulative dose effect increases.

What if semaglutide stops working after a few weeks? True tachyphylaxis (loss of effect over time at a constant dose) is rare with semaglutide. More commonly, patients reach a plateau where the current dose maintains appetite control but doesn't produce further weight loss. This is expected and signals the need for dose increase, dietary adjustment, or both. If appetite suppression disappears suddenly, check injection technique and medication storage.

How long does one semaglutide injection last? The half-life is approximately 7 days, meaning 50% of the dose is still circulating one week after injection. Appetite suppression is typically strongest on days 2-4 post-injection and gradually diminishes through day 7. The next injection is timed to occur before blood concentration drops below the therapeutic threshold.

Should I wait 5 weeks before judging if semaglutide works? No. You should notice some degree of appetite suppression within the first 2 weeks if the medication is going to work for you at the current dose. The 4-5 week timeline refers to reaching steady-state blood concentration, not the onset of any effect. Evaluate appetite control at week 2 and weight loss at week 6.

Can I speed up how fast semaglutide works? No. The absorption rate is determined by the subcutaneous depot pharmacokinetics and cannot be accelerated. Injecting more frequently (twice weekly instead of once weekly) does not speed onset and is not an approved protocol. The only way to increase effect magnitude is to increase dose, which should be done gradually to minimize side effects.

Does injection site affect how fast semaglutide works? Slightly. Abdominal injections have the most consistent absorption. Thigh injections may absorb slightly slower due to lower blood flow in that area. Upper arm injections have the most variable absorption because subcutaneous fat depth varies significantly in that location. For most patients, the difference is not clinically significant.

What if I don't feel semaglutide working until day 4 or 5? This is within the normal range. Peak concentration occurs 1-3 days post-injection, but individual variation in receptor sensitivity means some patients don't notice subjective effects until day 4 or 5. As long as you're experiencing appetite suppression before the next injection is due, the medication is working. If the effect wears off by day 6, discuss dose adjustment with your provider.

How long does nausea last after semaglutide injection? Nausea typically begins 24-48 hours post-injection and resolves within 3-4 days. It's most common during the first 2 weeks at a new dose and usually diminishes with subsequent injections at the same dose. If nausea persists beyond 4 days or is severe enough to cause vomiting, contact your provider. Persistent nausea may indicate the dose is too high or the titration was too fast.

Sources

1. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Pharmacology and Experimental Therapeutics. 2015.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. The Lancet. 2021.
4. Novo Nordisk. Ozempic (semaglutide) Prescribing Information. 2024.
5. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Journal of Clinical Pharmacology. 2015.
6. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
7. Nauck MA et al. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017.
8. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
9. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
10. Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017.
11. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk. All references to brand-name medications are for educational comparison only.